Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin and Venetoclax with Anti-CD20 in R/R FL and DLBCL
NCT02611323Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of polatuzumab vedotin and venetoclax in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Roche. Primary endpoints: Complete Response Rate at End of Induction, Adverse Events and Serious Adverse Events up to 56 months and 3 more. Started Mar 2016; status: completed.
02
Drugs
polatuzumab vedotinvenetoclax
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02611323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611323.